The primary objective of this study is to examine between-group differences in changes of objectively measured MVPA levels (min/week) among a randomly selected sample of office employees who are physically inactive in Hong Kong.
Regular participation in moderate-to-vigorous physical activity (MVPA) is related to decreased risk of morbidity and mortality. Among working populations, lack of MVPA may also be a risk factor for absenteeism and presenteeism. Both traditional workplace-based and web-based interventions have been suggested as being effective in promoting participation MVPA, health-related outcomes, and work-related productivity. However, several challenges limit their application in real world contexts. A 'blended' intervention approach combining the two intervention strategies is proposed to overcome these limitations. The proposed intervention aims to utilize the blended approach to increase participation in MVPA, health-related outcomes, and work productivity among inactive workers. Methods: The study will comprise of a three group cluster randomized controlled trial (cluster-RCT), comprising a three-month actual intervention and a nine-month behavioral follow-up period. The three groups will be: a web-based intervention group, a blended intervention group combining the web-based components with face-to-face workshops, and a control group. Physically inactive office employees (N = 141) from will be recruited and randomly assigned to the three groups by cluster randomization. The intervention mapping (IM) framework will be used for selecting and applying effective health behavioural theories and behavioural change techniques (BCTs) to the development, implementation and assessment of the intervention, which will be personally tailored. The primary outcome variable will be objectively measured MVPA using an accelerometer. Secondary outcomes will consist of indices of health including adiposity, blood pressure, blood sugar, blood lipids, self-reported depression, anxiety, stress, and health-related quality of life, and work-related variables including absenteeism and presenteeism.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
141
A blended intervention group combining the web-based components with face-to-face workshops and posters
A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters
Department of Sport, Physical Education, and Health
Kowloon Tong, Hong Kong
moderate-to-vigorous physical activity (MVPA) levels
examine between-group differences in changes of objectively measured MVPA levels (min/week) among a randomly selected sample of office employees who are physically inactive in Hong Kong
Time frame: baseline, 13 weeks, 25 weeks
changes of self-report MVPA levels (min/week)
To examine between-group differences in changes of self-reported MVPA levels (min/week) in different domains among the sample.
Time frame: baseline, 13 weeks, 25 weeks
Height in meters
Height will be measured to the nearest 0.1 cm using a stadiometer.
Time frame: baseline, 13 weeks, 25 weeks
Weight in kilograms
Weight will be measured to the nearest 0.1 kg on a calibrated digital balance scale (Seca, max. 200 kg, Germany) with the participants wearing lightweight clothing and no shoes.
Time frame: baseline, 13 weeks, 25 weeks
Body mass index (BMI, kg/m2)
Body mass index (BMI, kg/m2) will be calculated from weight and height.
Time frame: baseline, 13 weeks, 25 weeks
Waist circumference (cm)
Waist circumference (cm) will be measured midway between the lowest rib margin and the top of the iliac crest at the end of gentle expiration
Time frame: baseline, 13 weeks, 25 weeks
%Body fat
%BF will be assessed by a Tanita TBF-410 Body Composition Analyzer (Tanita Corporation, Tokyo, Japan) using foot-to-foot bioelectrical impedance analysis (BIA).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: baseline, 13 weeks, 25 weeks
Blood pressure (mmHg)
Blood pressure will be measured using the Omron M6 Compact (HEM-7000-E, Omron Healthcare Corporation, Kyoto, Japan) following standard measurement protocols.
Time frame: baseline, 13 weeks, 25 weeks
Hemoglobin A1C (%)
Hemoglobin A1C will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).
Time frame: baseline, 13 weeks, 25 weeks
Depression, anxiety and stress
Depression, anxiety and stress will be measured using the Chinese version of the Depression Anxiety Stress Scale (DASS-21)
Time frame: baseline, 13 weeks, 25 weeks
Presenteeism
It will be assessed using presenteeism questions derived from the WHO's Heath and Work Performance Questionnaire (HPO).
Time frame: baseline, 13 weeks, 25 weeks
High-density lipoprotein (mmol/L)
high-density lipoprotein will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).
Time frame: baseline, 13 weeks, 25 weeks
Triglyceride (mmol/L)
Triglyceride will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).
Time frame: baseline, 13 weeks, 25 weeks